Technical Analysis for IKT - Inhibikase Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -13.14% | |
| Stochastic Reached Oversold | Weakness | -13.14% | |
| Wide Bands | Range Expansion | -13.14% | |
| Oversold Stochastic | Weakness | -13.14% | |
| Fell Below 20 DMA | Bearish | -15.29% |
| Alert | Time |
|---|---|
| Down 5% | 3 days ago |
| Down 3% | 3 days ago |
| Fell Below Lower Bollinger Band | 3 days ago |
| Fell Below Previous Day's Low | 3 days ago |
| Down 2 % | 3 days ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Inhibikase Therapeutics, Inc. Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Parkinson's Disease Neurological Disorders Dementia Psychiatric Diagnosis Stage Pharmaceutical Treatment Of Parkinson's Disease Aging Associated Diseases Neurodegenerative Disorders Pyridines Lewy Body Dementia Imatinib Multiple System Atrophy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.82 |
| 52 Week Low | 0.8 |
| Average Volume | 608,582 |
| 200-Day Moving Average | 1.79 |
| 50-Day Moving Average | 1.83 |
| 20-Day Moving Average | 2.56 |
| 10-Day Moving Average | 2.62 |
| Average True Range | 0.33 |
| RSI (14) | 42.20 |
| ADX | 40.09 |
| +DI | 25.68 |
| -DI | 23.51 |
| Chandelier Exit (Long, 3 ATRs) | 2.69 |
| Chandelier Exit (Short, 3 ATRs) | 2.89 |
| Upper Bollinger Bands | 3.04 |
| Lower Bollinger Band | 2.08 |
| Percent B (%b) | -0.03 |
| BandWidth | 37.45 |
| MACD Line | 0.17 |
| MACD Signal Line | 0.27 |
| MACD Histogram | -0.0989 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.67 | ||||
| Resistance 3 (R3) | 2.70 | 2.52 | 2.56 | ||
| Resistance 2 (R2) | 2.52 | 2.37 | 2.51 | 2.53 | |
| Resistance 1 (R1) | 2.29 | 2.27 | 2.20 | 2.26 | 2.49 |
| Pivot Point | 2.11 | 2.11 | 2.07 | 2.10 | 2.11 |
| Support 1 (S1) | 1.88 | 1.96 | 1.79 | 1.85 | 1.61 |
| Support 2 (S2) | 1.70 | 1.86 | 1.69 | 1.57 | |
| Support 3 (S3) | 1.47 | 1.70 | 1.54 | ||
| Support 4 (S4) | 1.44 |
